α-methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro

Experimental Eye Research

Volumn 68, Issue 1, 1999, Pages 85-90

  Drago, Filippo ^a,b   Marino, Antonio ^a   La Manna, Carmen ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b Faculty of Medicine   (Italy)

Author keywords

Glaucoma; Iris pigmentation; Latanoprost; Melanogenesis; methyl p tyrosine

Indexed keywords

LATANOPROST; MELANIN; METIROSINE; MONOPHENOL MONOOXYGENASE;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME ANALYSIS; EYE COLOR; HUMAN; HUMAN CELL; IRIS; MELANOGENESIS; PRIORITY JOURNAL;

EID: 0033044826     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1006/exer.1998.0581     Document Type: Article

References (36)

1. Alm, A., Stjernschantz, J. and The Scandinavian Latanoprost Study Group (1995). Effects on intraocular pressure and side effects of 0·005% latanoprost once daily, evening or morning. A comparison with timolol. Ophthalmology 102, 1743-52.
2. Andley, U. P. and Clark, B. A. (1989). The effects of near-UV radiation on human lens β-crystallins. Photochem. Photobiol. 50, 97-105.
3. Bito, L. Z. (1997). Prostaglandins: A new approach to glaucoma management with a new, intriguing side effect. Surv. Ophthalmol. 41 (suppl. 2), 1-14.
4. Camras, C. B. and The United States Latanoprost Study Group (1996). Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-months, masked, multicenter trial in the United States. Ophthalmology 103, 138-47.
5. Camras, C. B., Siebold, E. C., Lustgarten, J. S., Serle, J. B., Frisch, S. C., Podos, S. M. and Bito, L. Z. (1989). Maintained reduction of intraocular pressure by prostaglandin F2α-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients. Ophthalmology 96, 1329-37.
6. Cruickshanks, K. J., Klein, R. and Klei, B. E. K. (1993). Sunlight and age-related macular degeneration: The beaver dam eye study. Arch. Ophthalmol. 111, 514-18.
7. Diestelhorst, M., Krieglstein, G. K., Lusky, M. and NagaSubramanian, S. (1997). Clinical dose-regimen studies with latanoprost, a new ocular hypotensive PGF2α analogue. Surv. Ophthalmol. 41, suppl (2), 77-81.
8. Dryia, T. P., O'Neil-Dryia, M., Pawelek, J. M. and Albert, D. M. (1978). Demonstration of tyrosinase in the adult bovine uveal tract and retinal pigment epithelium. Invest. Ophthalmol. Vis. Sci. 17, 511-14.
9. Gallagher, R. P., Elwood, J. M. and Rootman, J. 1985). Risk factors for ocular melanoma: Western Canada Melanoma study. J. Natl. Cancer Invest. 74, 775-8.
10. Gardner, J. M., Nakatsu, Y. and Gondo, Y. (1992). The mouse pink-eyed dilution gene: Association with human Prader-Willi and Angelman Syndromes. Science 257, 1121-4.
11. Goodall, T., Buffey, J. A. and Rennie, I. G. (1994). Effect of melanocyte stimulating hormone on human cultured choroidal melanocytes, uveal melanoma cells, and retinal epithelial cells. Invest. Ophthalmol. Vis. Sci. 35, 826-37.
12. Halaban, R. and Alfano, F. D. (1984). Selective elimination of fibroblasts from culture of human melanocytes. In Vitro 20, 447-50.
13. Hu, D. N., McCormick, S. A., Ritch, R. and Peiton-Henrion, K. (1993). Studies of human uveal melanocytes in vitro: Isolated purification and cultivation of human uveal melanocytes. Invest. Ophthalmol. Vis. Sci. 34, 2210-19.
14. Hu, D. N., McCormick, S. A., Orlow, S. J., Rosemblat, S., Lin, A. Y. and Wo, K. (1995). Melanogenesis by human uveal melanocytes in vitro. Invest. Ophthalmol. Vis. Sci. 36, 931-8.
15. Kerstetter, J. R., Brubaker, R. F., Wilson, S. E. and KullerStrand, L. J. (1988). Prostaglandin F2α-L-isopropylester lowers intraocular pressure without decreasing aqueous humor flow. Am. J. Ophthalmol. 105, 30-4.
16. Laties, A. M. (1974). Ocular melanin and the adrenergic innervation to the eye. Trans. Am. Ophthalmol. Soc. 72, 560-605.
17. Lindsey, J. D., Kashiwagi, K., Kashiwagi, F. and Weinreb, R. (1997). Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: Implications for uveoscleral outflow. Surv. Ophthalmol. 41 (suppl. 2), 53-9.
18. Lefkowitz, R. J., Hoffman, B. B. and Taylor, P. (1996). Neurotransmission. In: Goodman & Gilman's the Pharmacological Basis Of Therapeutics (Hardman, J. G., Limbird, L. E., Molinoff, P. B., Ruddon, R. W. and Goodman Gilman, A. Eds), Pp. 105-9. McGraw-Hill: New York, U.S.A.
19. Mishima, H. K., Kiuchi, Y., Takamatsu, M., Racz, P. and Bito, L. Z. (1997). Circadian intraocular pressure management with latanoprost: Diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. Surv. Opththalmol. 41 (suppl. 2), 139-44.
20. Naeyaert, J. M., Eller, M., Gordon, P. R., Park, H. Y. and Gilchrest, B. A. (1991). Pigment content of cultured human melanocytes does not correlate with tyrosinase message level. Br. J. Dermatol. 125, 297-303.
21. Norose, K., Yano, A., Aosai, F. and Segrawa, K. (1990). Immunologic analysis of cerebrospinal fluid lymphocytes in vogt-koyanagi-harada disease. Invest. Ophthalmol. Vis. Sci. 31, 1210-16.
22. Orlow, S. J., Chakraborty, A. K., Boissy, R. E. and Pawelek, J. M. (1990). Inhibition of induced melanogenesis in cloundman melanoma cells by four phenotypic modifiers. Exp. Cell Res. 191, 209-18.
23. Prota, G. (1993). Regulatory mechanisms of melanogenesis: Beyond the tyrosinase concept. J. Invest. Dermatol. 100, 156S-61S.
24. Sakamoto, T., Murata, T. and Inomata, H. (1991). Class II major histocompatibility complex on melanocytes of Vogt-Koyanagi-Harada disease. Arch. Ophthalmol. 109, 1270-4.
25. Sarna, T. (1992). Properties and function of the ocular melanin: A photobiophysical review. J. Photochem. Photobiol. 12, 215-58.
26. Selen, G., Stjernschantz, J. and Resul, B. (1997). Prostaglandin-induced iridial pigmentation in primates. Surv. Ophthalmol. 41 (suppl. 2), 125-8.
27. Spector, A. (1984). The search for a solution to senile cataract. Invest. Ophthalmol. Vis. Sci. 25, 130-46.
28. Taylor, H. R., West, S. K., Munoz, H. S., Newland, H. S., Abbey, H. and Emmett, E. A. (1988). Effect of ultraviolet radiation in cataract formation. N. Engl. J. Med. 319, 1429-33.
29. Toris, C. B., Camras, C. B. and Yablonski, M. E. (1993). Effects of PhXA41, a new prostaglandin F2α analog on aqueous humor dynamics in human eyes. Ophthalmology 100, 1297-304.
30. Tucker, M. A., Shields, J. A., Hartge, P., Augsburger, J., Hoover, R. N. and Fraumeni, J. F. (1985). Sunlight exposure as risk factor for intraocular malignant melanoma. N. Engl. J. Med. 313, 789-92.
31. Urabe, K., Aroca, P. and Hearing, V. (1993). From gene to protein: Determination of melanin synthesis. Pigment Cell Res. 6, 186-92.
32. Waldrep, J. C. and Kaplan, H. J. (1986). Human choridal melanocytes in tissue culture. Curr. Eye Res. 5, 587-91.
33. Watson, P., Stjernschantz, J. and The Latanoprost Study Group (1996). A six month randomized double-masked study comparing latanoprost to timolol in open angle glaucoma and ocular hypertension. Ophthalmology 103, 126-37.
34. Weiner, N. (1985). Drugs that inhibit adrenergic nerves and block adrenergic receptors. In: Goodman & Gilman's the Pharmacological Basis of Therapeutics (Gilman, A., Goodman, L. S., Rall, T. W., Murad, F. Eds), Pp. 181-214. McMillan: New York, U.S.A.
35. Weiter, J. J., Delori, F. C., Wing, G. L. and Fitch, K. A. (1986). Retinal pigment epithelial lipofuscin and melanin and choroidal melanin in human eyes. Invest. Ophthalmol. Vis. Sci. 27, 145-52.
36. Wistrand, P. J., Stjernschantz, J. and Olsson, K. (1997). The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv. Ophthalmol. 41 (suppl. 2), 129-38.